Once known exclusively for their role in nutrients absorption, primary bile acids,
chenodeoxycholic and cholic acid, and secondary bile acids, deoxycholic and lithocholic …

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious
health problems worldwide. These two diseases have similar pathological spectra, ranging …

The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile
acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases …

The bile acid receptor FXR has emerged as a bona fide drug target for chronic cholestatic
and metabolic liver diseases, ahead of all non-alcoholic fatty liver disease (NAFLD). FXR is …

Background & Aims Steroidal farnesoid X receptor (FXR) agonists demonstrated potent anti-
fibrotic activities and lowered portal hypertension in experimental models. The impact of the …

This is difficult to judge because the data available from clinicalstage FXR agonists in NASH
cannot be compared one to one simply because the trial protocols differ from each other in …

Non-alcoholic fatty liver disease (NAFLD) is the most frequent type of chronic liver disease in
the pediatric age group, paralleling an obesity pandemic. A “multiple-hit” hypothesis has …

Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for
the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects …